|Bid||425.75 x 900|
|Ask||443.71 x 1300|
|Day's range||434.57 - 441.97|
|52-week range||331.75 - 446.95|
|Beta (5Y monthly)||0.60|
|PE ratio (TTM)||16.47|
|Earnings date||01 Nov 2023|
|Forward dividend & yield||2.48 (0.56%)|
|Ex-dividend date||31 Aug 2023|
|1y target est||478.75|
Veradigm's (MDRX) latest partnership is likely to promote value-based care initiatives for healthcare providers and the patients they serve.
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. MOD, SFM, MOH and MCK are sound enough to meet financial obligations.
Ecolab's (ECL) strength in its business raises optimism about the stock.